Immutep (Immutep) Price-to-Operating-Cash-Flow : (As of Apr. 25, 2024)

View and export this data going back to 1988. Start your Free Trial

What is Immutep Price-to-Operating-Cash-Flow?

As of today (2024-04-25), Immutep's share price is $2.5526. Immutep's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.27. Hence, Immutep's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Immutep's Price-to-Operating-Cash-Flow or its related term are showing as below:

IMMP's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 24.7
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Immutep's Cash Flow from Operations per share for the three months ended in Dec. 2023 was $-0.03. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.27.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -15.40% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -4.10% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 11.50% per year.

During the past 13 years, Immutep's highest 3-Year average Operating Cash Flow per Share Growth Rate was 32.20% per year. The lowest was -55.40% per year. And the median was 5.80% per year.

Immutep Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Immutep's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immutep Price-to-Operating-Cash-Flow Chart

Immutep Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

Immutep Quarterly Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Immutep's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Immutep's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immutep's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immutep's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Immutep's Price-to-Operating-Cash-Flow falls into.

Immutep Price-to-Operating-Cash-Flow Calculation

Immutep's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	2.5526	/	-0.267
	=

Immutep's Share Price of today is $2.5526.
Immutep's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.27.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Immutep Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Immutep's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Immutep (Immutep) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immutep Ltd (NAS:IMMP) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

PRRUF:USA YP1B:Germany IMM:Australia

Address

264 George Street, Level 33, Australia Square, Sydney, NSW, AUS, 2000

Website

https://www.immutep.com

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia and derives the majority of the revenue from the sale of the products.